Abstract
Plexiform neurofibromas (PNF), one of the major features of neurofibromatosis type 1 (NF1), are characterized by complex cellular composition and mostly slow but variable growth patterns. In this study, we examined the effect of imatinib mesylate, a receptor tyrosine kinase inhibitor, on PNF-derived Schwann cells and PNF tumour growth in vitro and in vivo. In vitro, PNF-derived primary Schwann cells express platelet-derived growth factors receptors (PDGFR) alpha and beta, both targets of imatinib, and cell viability was reduced by imatinib mesylate, with 50% inhibition concentration (IC(50)) of 10 microM. For in vivo studies, PNF tumour fragments xenografted onto the sciatic nerve of athymic nude mice were first characterized. The tumours persisted for at least 63 days and maintained typical characteristics of PNFs such as complex cellular composition, low proliferation rate and angiogenesis. A transient enlargement of the graft size was due to inflammation by host cells. Treatment with imatinib mesylate at a daily dose of 75 mg/kg for 4 weeks reduced the graft size by an average of 80% (n = 8), significantly different from the original sizes within the group and from sizes of the grafts in 11 untreated mice in the control grou...Continue Reading
References
Jul 2, 1997·JAMA : the Journal of the American Medical Association·D H GutmannD Viskochil
Jun 20, 1998·Neurology·J H TonsgardA H Dachman
May 16, 2002·Journal of Medical Genetics·D G R EvansA Moran
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Jun 23, 2004·Neurobiology of Disease·Silke FrahmLan Kluwe
Jul 9, 2004·Journal of Biomedicine & Biotechnology·Dusica Babovic-VuksanovicJeffrey L. Platt
Dec 17, 2005·Carcinogenesis·Nikola HoltkampAndreas von Deimling
Jan 25, 2006·Neuroradiology·V F MautnerC Fünsterer
Aug 29, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Sébastien BihorelJean-Michel Scherrmann
Oct 28, 2006·Blood·Ellen WeisbergJames D Griffin
Dec 8, 2006·The New England Journal of Medicine·Brian J DrukerUNKNOWN IRIS Investigators
Mar 6, 2007·Journal of Neuroscience Research·George Q PerrinDavid Muir
Apr 30, 2008·Human Molecular Genetics·Elisabeth A LasaterFang Li
Nov 6, 2008·Cell·Feng-Chun YangD Wade Clapp
Citations
Mar 27, 2015·EMBO Molecular Medicine·Joan CastellsaguéConxi Lázaro
May 27, 2017·Oncotarget·Corina AnastasakiDavid H Gutmann
Nov 15, 2011·Annual Review of Pathology·Karl StaserD Wade Clapp
Sep 7, 2013·PLoS Genetics·GuangJun ZhangJacqueline A Lees
Oct 24, 2014·PloS One·Jiang WeiAndreas Kurtz
Mar 30, 2018·The Journal of Clinical Investigation·Chung-Ping LiaoLu Q Le
Apr 19, 2018·Expert Opinion on Therapeutic Targets·James A Walker, Meena Upadhyaya
Nov 1, 2013·Journal of Neuro-oncology·Wei JiangLan Kluwe
Sep 7, 2013·Veterinary Pathology·S SuzukiH Nakayama
Jul 30, 2018·BMC Research Notes·Susan Fischer-HuchzermeyerAnja Harder
Jun 23, 2012·Pediatric Radiology·Boaz KarmazynKent A Robertson
Apr 5, 2017·Khirurgiia·A G KrigerYu S Gal'china
Apr 29, 2015·Current Treatment Options in Neurology·Caterina SabatiniSusanna Esposito
Jul 16, 2013·International Journal of Endocrinology and Metabolism·Gul BanoStephen Schey
Apr 11, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Parag P PatwardhanGary K Schwartz
Aug 31, 2019·Dermatologic Clinics·Benjamin Becker, Roy E Strowd
Aug 12, 2021·Indian Journal of Dermatology, Venereology and Leprology·Kaberi Feroze, Feroze Kaliyadan
Dec 22, 2021·Expert Opinion on Investigational Drugs·Simge AcarAngela C Hirbe